Home > Drugs A – Z > Temozolomide
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Temozolomide

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

By mouth

Temozolomide is used to treat specific types of brain cancer (eg, glioblastoma multiforme, anaplastic astrocytoma) in patients whose tumors have returned… Read more

Brand names include: Temodar

Injection

Temozolomide injection is used to treat specific types of brain cancer (eg, glioblastoma multiforme, anaplastic astrocytoma) in patients whose tumors… Read more

Brand names include: Temodar

Drug classes About this
Antineoplastic Agent

What works? Research summarized

Evidence reviews

Radiotherapy combined with temozolomide treatment for glioblastoma multiforme: a meta-analysis

Bibliographic details: Wang XH, Guo LY, Ma B, Yang KH, Zhang QN, Cao N, Ye XP.  Radiotherapy combined with temozolomide treatment for glioblastoma multiforme: a meta-analysis. Tumor 2010; 30(12): 1056-1064

[Three dimensional conformal radiotherapy concurrent combined with temozolomide treatment for postoperative high grade glioma: a meta analysis]

Bibliographic details: Chen WF, Wu QL, Mo LG.  [Three dimensional conformal radiotherapy concurrent combined with temozolomide treatment for postoperative high grade glioma: a meta analysis]. Chinese Journal of Cancer Prevention and Treatment 2014; 21(7): 543-551

Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis

Temozolomide (TMZ) has received much attention, notably in the treatment of malignant glioma and malignant melanoma. The objective of this study was to compare the clinical efficacy and safety of TMZ alone and TMZ-based combination drug therapy in patients with melanoma. Using "temozolomide" as a keyword combined with "melanoma" and "randomized controlled trials" as Medical Subject Headings, the following electronic databases were searched: the Cochrane library, MEDLINE, EBSCO, EMBASE, Ovid, cNKI, and cBMDisc. The evaluating indicators were overall response rate (ORR), 1-year survival rate, and several of the most frequent adverse events. Five randomized controlled trials met our criteria and were included in the meta-analysis, with a total of 703 participants (309 patients received TMZ alone, and 394 patients received combined regimens). The meta-analysis showed that the ORR for TMZ-based drug therapy was higher than TMZ alone [relative risk (RR) = 1.44; 95% confidence interval (CI), 1.06-1.95], but the 1-year survival rate was not significantly different between the two groups (RR = 1.13; 95% CI, 0.92-1.40). These results suggested that the impact of these increased response rates was not translated into a survival benefit. Moreover, we found no difference in the incidence of adverse events analyzed. The currently available evidence showed that the TMZ-combination therapy may moderately improve the response rate, but there was no corresponding increased toxicity. Future large-scale, high-quality, placebo-controlled, double-blind trials are needed.

See all (24)

Summaries for consumers

Temozolomide for brain cancer

High grade glioma (HGG) is a rapidly progressive form of brain cancer with a poor survival rate even after standard treatment with surgery and radiotherapy. Temozolomide is an oral anti‐cancer drug.

Treatment of high grade glioma with anti‐cancer drug (chemotherapy) coated implants

High grade glioma is a rapidly progressive form of brain tumour. Standard therapy involves the use of surgery (either biopsy or resection) and radiotherapy plus or minus temozolomide. Chemotherapy was not previously used due to concerns over efficacy and high risks of side effects.

Does giving chemotherapy, radiotherapy or both improve survival in people with rare (anaplastic oligodendrogliomas and oligoastrocytomas) brain tumours?

Traditionally, the standard of care for people with rare anaplastic oligodendrogliomas and anaplastic oligoastrocytomas (brain tumours) has been surgery followed by radiotherapy. However, the benefit of adjuvant (post‐surgery) chemotherapy and radiotherapy is still unclear. In addition, the value of chromosome markers is also under investigation.

See all (4)

PubMed Health Blog...

read all...